Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: atorvastatin calcium

« Back to Dashboard

Summary for Generic Name: atorvastatin calcium

Tradenames:3
Patents:5
Applicants:9
NDAs:10
Drug Master File Entries: see list57
Suppliers: see list17
Therapeutic Class:Cardiovascular Agents

Pharmacology for Ingredient: atorvastatin calcium

Clinical Trials for: atorvastatin calcium

Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia
Status: Completed Condition: Hypertriglyceridemia

Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy
Status: Withdrawn Condition: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer

Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Under Fed Conditions
Status: Completed Condition: Healthy

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
Status: Completed Condition: Atypical Ductal Breast Hyperplasia; Breast Cancer; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ

Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg Under Fasting Conditions
Status: Completed Condition: Healthy

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
Status: Recruiting Condition: Graft vs Host Disease

High Dose and Low Dose of Atorvastatin in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)
Status: Completed Condition: Cardiovascular Disease

Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.
Status: Completed Condition: HIV; Hypercholesterolaemia

Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting
Status: Active, not recruiting Condition: CVD

Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus
Status: Terminated Condition: Avascular Necrosis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ranbaxy Labs Ltd
ATORVASTATIN CALCIUM
atorvastatin calcium
TABLET;ORAL076477Nov 30, 2011RXNo<disabled><disabled>
Pfizer
LIPITOR
atorvastatin calcium
TABLET;ORAL020702Apr 7, 2000RXYes5,686,104*PED<disabled>Y<disabled>
Merck Sharp Dohme
LIPTRUZET
atorvastatin calcium; ezetimibe
TABLET;ORAL200153May 3, 2013RXYes5,846,966*PED<disabled>Y<disabled>
Merck Sharp Dohme
LIPTRUZET
atorvastatin calcium; ezetimibe
TABLET;ORAL200153May 3, 2013RXNo<disabled><disabled>
Merck Sharp Dohme
LIPTRUZET
atorvastatin calcium; ezetimibe
TABLET;ORAL200153May 3, 2013RXYesRE42461*PED<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc